Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression

Abstract

Objectives While most women with ovarian cancer will achieve complete remission after treatment, the majority will relapse within two years, highlighting the need for novel therapies. Cancer stem cells (CSC) have been identified in ovarian cancer and most other carcinomas as a small population of cells that can self-renew. CSC are more chemoresistant and radio-resistant than the bulk tumor cells; it is likely that CSC are responsible for relapse, the major problem in cancer treatment. CD133 has emerged as one of the most promising markers for CSC in ovarian cancer. The hypothesis driving this study is that despite their low numbers in ovarian cancer tumors, CSC can be eradicated using CD133 targeted therapy and tumor growth can be inhibited. Methods Ovarian cancer cell lines were evaluated using flow cytometry for expression of CD133. In vitro viability studies with an anti-CD133 targeted toxin were performed on one of the cell lines, NIH:OVCAR5. The drug was tested in vivo using a stably transfected luciferase-expressing NIH:OVCAR5 subline in nude mice, so that tumor growth could be monitored by digital imaging in real time. Results Ovarian cancer cell lines showed 5.6% to 16.0% CD133 expression. dCD133KDEL inhibited the in vitro growth of NIH:OVCAR5 cells. Despite low numbers of CD133-expressing cells in the tumor population, intraperitoneal drug therapy caused a selective decrease in tumor progression in intraperitoneal NIH: OVCAR5-luc tumors. Conclusions Directly targeting CSC that are a major cause of drug resistant tumor relapse with an anti-CD133 targeted toxin shows promise for ovarian cancer therapy.

Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells

“…15 We have reported that CXCR1 blockade selectively targeted human breast CSCs in vitro and in xenografts. 16 Nevertheless, the strategies designed to specifically target CSCs in vivo remain largely unexplored.…”

Review: Mechanotransduction in ovarian cancer: Shearing into the unknown

“…28 Recent clinical studies and xenograft research have shown that side populations of ovarian cancer within the ascites display characteristics of CSCs. 126,127 These ovarian CSCs have heightened chemoresistance, the ability to asymmetrically proliferate, and the capacity to self-renew.…”

Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer

“…Together with the enzymatic activity of ALDH, the expression of CD133 is considered a marker of ovarian CSCs and is associated with drug resistance (27,42,43 ÃÃÃÃ , P < 0.0001 drug versus medium. Values in the bar graph represent the mean AE SEM of 3 different experiments.…”